New data show that migraine patients treated with Biohaven’s Nurtec ODT decreased their use of opioids.
“Results demonstrate a clinically meaningful reduction in opioid use in this patient population and may be of benefit to those reliant on opioids to manage their disease, thereby alleviating potential negative consequences of opioid use,” the company says.